期刊
NATURE REVIEWS CANCER
卷 18, 期 12, 页码 767-777出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41568-018-0076-6
关键词
-
类别
资金
- US National Cancer Institute (NCI) [R01CA123031, R01CA94184, P01CA203657, UO1CA176287, R35CA210018]
The three RAS genes-HRAS, NRAS and KRAS-are collectively mutated in one-third of human cancers, where they act as prototypic oncogenes. Interestingly, there are rather distinct patterns to RAS mutations; the isoform mutated as well as the position and type of substitution vary between different cancers. As RAS genes are among the earliest, if not the first, genes mutated in a variety of cancers, understanding how these mutation patterns arise could inform on not only how cancer begins but also the factors influencing this event, which has implications for cancer prevention. To this end, we suggest that there is a narrow window or 'sweet spot' by which oncogenic RAS signalling can promote tumour initiation in normal cells. As a consequence, RAS mutation patterns in each normal cell are a product of the specific RAS isoform mutated, as well as the position of the mutation and type of substitution to achieve an ideal level of signalling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据